Investment Rating - The report maintains a "Buy" rating for the company [1][6][12] Core Views - The company is expected to continue its strong profit growth in Q4 2025, with a positive outlook for revenue and profit performance in 2026 [2][12] - The target price is set at 24.80 CNY per share, based on a 20x PE ratio for 2026E [12][14] Financial Summary - Total revenue is projected to decline from 1,748 million CNY in 2023 to 1,555 million CNY in 2024, before recovering to 1,681 million CNY in 2025 and reaching 1,869 million CNY in 2026 [4][13] - Net profit attributable to the parent company is expected to decrease from 146 million CNY in 2023 to 121 million CNY in 2024, then rebound to 187 million CNY in 2025 and further to 238 million CNY in 2026 [4][13] - Earnings per share (EPS) is forecasted to be 0.76 CNY in 2023, decreasing to 0.63 CNY in 2024, and then increasing to 0.98 CNY in 2025 and 1.24 CNY in 2026 [4][13] - The return on equity (ROE) is projected to improve from 7.5% in 2023 to 11.3% in 2026 [4][13] Market Data - The company's market capitalization is approximately 3,670 million CNY, with a share price range of 14.28 to 22.05 CNY over the past 52 weeks [7][12] - The current share price is 19.17 CNY [12] Production Capacity and Growth - New production capacity is expected to be released gradually, contributing to steady revenue growth [12] - A 30,000-ton soybean protein production line is anticipated to be operational by December 2026, with an expected annual revenue of 260 million CNY [12]